The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.
Alkermes' (ALKS) earnings and revenues miss first-quarter 2024 estimates. However, revenues rise year over year on strong proprietary product sales.
Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk. In connection with the closing of the transaction, Alkermes will receive a one-time cash payment for the facility and certain related assets of approximately $91 million.